Female Infertility. inability to achieve a pregnancy
Conditions
Interventions
Intervention 1: The Control group:
The participants in the control group do not receive any additional treatment before embryo transfer. Intervention 2: The Intervention group:
The participants in the
Treatment - Drugs
The Control group:
The participants in the control group do not receive any additional treatment before embryo transfer.
The Intervention group:
The participants in the intervention group receive a single dose of 300 µgr GCSF subcutaneously one hour before the embryo transfer process.
Sponsors
Research Deputy, Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 39 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1. age < 40 years 2. having = 2 failed IVF attempts where at least 3 good embryos were transferred 3. the lack of contraindications for GCSF treatment (sickle cell disease, chronic neutropenia, known past or present malignancy, renal insufficiency, upper respiratory infection, pneumonia, and congenital fructose intolerance) 4. not having any systemic disease Exclusion Criteria: 1. having inadequate thin endometrium (< 7mm) on the day of hCG injection 2. the detection of Asherman’s syndrome, fibroids, and polyps in diagnostic hysteroscopy 3. having any medical illness upon enrollment (including hypertension, diabetes, antiphospholipid syndrome, systemic lupus erythematosus, thrombophilia, thyroid disorders) 4. refusing to give an informed consent to participate in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chemical pregnancy. Timepoint: 2 weeks after IVF and embryo transfer. Method of measurement: serum ß-HCG level. | — |
Secondary
| Measure | Time frame |
|---|---|
| Implantation. Timepoint: 4 weeks after IVF and embryo transfer. Method of measurement: transvaginal sonography to detect gestational sacs.;Clinical Pregnancy. Timepoint: 6 weeks after embryo transfer. Method of measurement: detection of gestational sac and fetal heart rate on transvaginal sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mahdi Sheikh
Maternal Fetal and Neonatal Research Center, Tehran University of Medical Sciences
Outcome results
None listed